Bristol-Myers reviews $100m US media work

- The pharmaceuticals company, Bristol-Myers Squibb, has put its estimated $100 million (£60 million) US consumer prescription drug media business up for review.

- The pharmaceuticals company, Bristol-Myers Squibb, has put its estimated $100 million (£60 million) US consumer prescription drug media business up for review.

The account is currently handle by Western International Media, California. The business includes the Pravachol cholesterol-reduction brand, which makes up the bulk of the spending, but also includes Buspar anxiety and Zerit HIV treatments.





Topics

Become a member of Campaign

Get the very latest news and insight from Campaign with unrestricted access to campaignlive.co.uk , plus get exclusive discounts to Campaign events

Become a member

Looking for a new job?

Get the latest creative jobs in advertising, media, marketing and digital delivered directly to your inbox each day.

Create an alert now

Partner content